Laboratory Corp. of America (NYSE:LH) will be posting its quarterly earnings results before the market opens on Tuesday, April 30th. Analysts expect Laboratory Corp. of America to post earnings of $2.53 per share for the quarter. Laboratory Corp. of America has set its FY 2019 guidance at $11.00-11.40 EPS and its FY19 guidance at $11.00-11.40 EPS.
Laboratory Corp. of America (NYSE:LH) last released its earnings results on Thursday, February 7th. The medical research company reported $2.52 EPS for the quarter, topping analysts’ consensus estimates of $2.48 by $0.04. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The firm had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.78 billion. During the same period in the prior year, the firm posted $2.45 earnings per share. The company’s quarterly revenue was up 1.6% on a year-over-year basis. On average, analysts expect Laboratory Corp. of America to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
NYSE LH opened at $144.25 on Tuesday. Laboratory Corp. of America has a 12 month low of $119.38 and a 12 month high of $190.35. The firm has a market capitalization of $14.43 billion, a PE ratio of 13.09, a P/E/G ratio of 1.48 and a beta of 1.15. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.51.
Several research firms recently commented on LH. ValuEngine cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Monday, January 7th. Morgan Stanley set a $175.00 price objective on Laboratory Corp. of America and gave the company a “buy” rating in a research report on Friday, February 22nd. TheStreet cut Laboratory Corp. of America from a “b-” rating to a “c+” rating in a research report on Friday, January 11th. Zacks Investment Research raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. Finally, UBS Group set a $178.00 price objective on Laboratory Corp. of America and gave the company a “buy” rating in a research report on Friday, February 8th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $175.50.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.com-unik.info/2019/04/23/laboratory-corp-of-america-lh-set-to-announce-quarterly-earnings-on-tuesday.html.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Recommended Story: How to find the components of the quick ratio
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.